HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jackson, C. W. Articles by Reddan, J. G. Search for Related Content PubMed PubMed Citation Articles by Jackson, C. W. Articles by Reddan, J. G.

CHERRY W. JACKSON, PHARM.D., BCPP, is Professor of Pharmacy Practice, Harrison School of Pharmacy, Auburn University, Auburn University, AL. AMY HECK SHEEHAN, PHARM.D., is Associate Professor of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, Purdue University, Indianapolis IN, and Drug Information Specialist, Clarian Health Partners, Indianapolis. JENNIFER G. REDDAN, PHARM.D., is Manager, Drug Use Policy, Clarian Health Partners.

Address correspondence to Dr. Jackson at the Harrison School of Pharmacy Auburn University, 217 Walker Building, Auburn, AL 36849-8353 (cwj0002{at}auburn.edu).

Purpose. Data collected from the Food and Drug Administration (FDA) under the Freedom of Information Act are presented to help clinicians understand the data prompting the black-box warning for droperidol and to make educated decisions regarding the use of droperidol and alternative agents. Summary. A written request was submitted to FDA to provide a report of any and all reports of cardiovascular adverse events related to droperidol that were part of the decision to add a black-box warning to the label of droperidol. The report listed 277 cases of adverse effects associated with droperidol since its introduction to the market in 1970. Many of the reports were duplicates, leaving a total of 65 individual cases. Of these cases, only 2 described adverse effects possibly caused by droperidol in dosages commonly used in the United States. In addition to these reports, the results of two European studies prompted FDA to make the decision for the black-box warning. Both studies used droperidol doses 50–100 times higher than those used in the United States. Conclusion. Studies show that there is a dose-dependent increase in the rate of adverse cardiovascular events when droperidol is used either alone or in combination with other medications that cause Q-T interval prolongation. At this time, there does not appear to be significant evidence to suggest that serotonin type 3-receptor (5-HT3) antagonists are safer than droperidol with regard to Q-T interval prolongation. More studies are needed to determine the safety and efficacy of droperidol when used in doses of 0.625–1.25 mg compared with the 5-HT3 antagonists. Index terms: Anxiolytics, sedatives and hypnotics; Dosage; Droperidol; Food and Drug Administration (U.S.); Labeling; Toxicity

 

This article has been cited by other articles:

				D. D. Kloth New pharmacologic findings for the treatment of PONV and PDNV Am. J. Health Syst. Pharm., January 1, 2009; 66(1_Supplement_1): S11 - S18. [Abstract] [Full Text] [PDF]

				A. R. J. Wyllie, V. V. Carvalhana, L. D. Burry, and J. E. Teresi Sufficiency of data for resuming use of low-dose droperidol Am. J. Health Syst. Pharm., February 1, 2008; 65(3): 201 - 201. [Full Text] [PDF]